- FDA decision expected by December 2026 on sBLA for obinutuzumab (Gazyva/Gazyvaro) in SLE
- Phase III ALLEGORY (n~300) primary endpoint SRI-4 at 52 weeks: 76.7% vs 53.5% (adjusted diff 23.1%, 95% CI 12.5-33.6; p<0.001); hazard ratio for flare 0.58 (95% CI 0.40-0.82; p=0.002)
- Secondary outcomes: DORIS remission 33.8% vs 13.8% (adj diff 19.9%); LLDAS 57.6% vs 25.0% (adj diff 32.6%); sustained glucocorticoid reduction to <=7.5 mg/day (weeks 40-52); safety consistent with known profile
Regulatory status
FDA accepted Roche's supplemental BLA for obinutuzumab (Gazyva/Gazyvaro) in systemic lupus erythematosus (SLE); a decision is expected by December 2026; Gazyva is already approved for lupus nephritis in the US and EU.
ALLEGORY primary outcome
Phase III ALLEGORY met its primary endpoint: SRI‑4 at 52 weeks was 76.7% with obinutuzumab plus standard therapy versus 53.5% with placebo (adjusted difference 23.1%, 95% CI 12.5–33.6; p<0.001).
Secondary outcomes
Key secondary results included DORIS remission 33.8% vs 13.8% (adjusted difference 19.9%), LLDAS 57.6% vs 25.0% (adjusted difference 32.6%), a hazard ratio for BILAG‑defined flare of 0.58 (95% CI 0.40–0.82; p=0.002), and sustained glucocorticoid reduction to ≤7.5 mg/day from weeks 40–52.
Safety
Safety was consistent with the established obinutuzumab profile and no new safety signals were identified.
Study design and context
ALLEGORY was a randomized, double‑blind, placebo‑controlled phase III trial enrolling ~300 adults (1:1 randomization) with a 52‑week blinded period and an open‑label extension to 104 weeks; results were presented at SLEuro 2026 and published in NEJM (March 2026); data have also been used for an EMA filing and add to other positive phase III studies (REGENCY, INShore, MAJESTY).
Mechanism
Obinutuzumab is a glycoengineered Type II anti‑CD20 monoclonal antibody designed to induce direct B‑cell death and enhance antibody‑dependent cellular cytotoxicity (ADCC).
